OpenAI Debuts GPT-Rosalind for Faster Drug Discovery

OpenAI introduced GPT-Rosalind on April 19, 2026, marking its first specialized reasoning model for the life sciences sector ^[1]. The tool focuses on biochemistry, genomics, and protein engineering to help researchers synthesize evidence and generate fresh hypotheses ^[1][3]. Researchers intend to use the model to shorten drug development timelines ^[1]. Initial partners utilizing the platform include pharmaceutical leaders Amgen and Moderna, alongside the Allen Institute ^[1][3]. This move represents the company's first purpose-built model for a specific industry ^[3]. By targeting biotech, OpenAI seeks a larger share of the enterprise pharmaceutical market ^[2][3].